Cataldo M G, D'Aiuto A, Bongiorno A
Istituto di Clinica Medica B, Università degli Studi di Palermo.
Minerva Dietol Gastroenterol. 1990 Jan-Mar;36(1):27-30.
It is well known that prolonged use of Non Steroidal Anti-inflammatory Drugs (NSAIDs) can trigger gastroduodenal lesions and/or their complications, even in the absence of any dramatic painful and dyspeptic symptomatology. The paper reports the results of a double-blind study carried out with Colloidal Bismuth Subcitrate (CBS, DE-NOL), an antiulcer drug with cytoprotective activity, versus ranitidine (RN) with the aim of assessing its therapeutic efficacy in promoting healing of either gastric or duodenal ulcers induced by NSAIDs. It is concluded that the efficacy of DE-NOL is comparable to that of RN, although some minor differences in healing rates were observed: these being in favour of DE-NOL in the gastric ulcer patients and in favour of RN in the duodenal ulcer patients, respectively. In addition, it is stated that in patients undergoing chronic treatment with NSAIDs the use of cytoprotective drugs as a preventive treatment as well as periodic endoscopic surveillance are more useful and rational in order to combat the onset of NSAIDs-induced side-effects, given the frequent paucity of symptomatology following the occurrence of gastroduodenal lesions.
众所周知，长期使用非甾体抗炎药（NSAIDs）可引发胃十二指肠病变和/或其并发症，即便没有任何明显的疼痛和消化不良症状。本文报告了一项双盲研究的结果，该研究对比了具有细胞保护活性的抗溃疡药物枸橼酸铋钾（CBS，得乐）和雷尼替丁（RN），旨在评估其促进NSAIDs所致胃溃疡或十二指肠溃疡愈合的治疗效果。研究得出结论，得乐的疗效与雷尼替丁相当，尽管观察到愈合率存在一些细微差异：胃溃疡患者中得乐更具优势，十二指肠溃疡患者中雷尼替丁更具优势。此外，文中指出，鉴于胃十二指肠病变发生后症状往往不明显，对于接受NSAIDs长期治疗的患者，使用细胞保护药物进行预防性治疗以及定期进行内镜监测，对于对抗NSAIDs引起的副作用更为有用且合理。
